Certain genetic mutations in melanoma, including JAK1, JAK2, B2M and PTEN, etc., correlate with negative treatment response of PD-1 blockade therapy, while BRCA2 mutations were reported enriched in melanomas responsive to this treatment [30, 31]. Here, PDCD1 is linked to melanoma.